On February 13, 2019, the Board of Directors of Catabasis Pharmaceuticals, Inc. elected Joanne T. Beck, Ph.D. as a director, effective immediately. Dr. Beck will serve as a Class II director with a term expiring at the Company’s 2020 annual meeting of the stockholders of the Company and until such time as her successor is duly elected and qualified, or until her earlier death, resignation or removal. Dr. Beck will serve as a member of the Science & Technology committee of the Board. Dr. Beck has served as the Executive Vice President of Pharmaceutical Development and Operations and as a member of the Executive Committee at Celgene, a publicly held biopharmaceutical company, since 2016. Prior to Celgene, Dr. Beck worked at Shire, where she served as Senior Vice President of pharmaceutical development from 2012 to 2016. On February 13, 2019, Michael Ross, Ph.D. notified the Company of his decision to resign as a member of the Board, effective as of February 14, 2019.